Artiva Biotherapeutics Inc is a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies for patients with autoimmune diseases and cancers. The company's lead product candidate AlloNK is an allogeneic off-the-shelf cryopreserved NK cell therapy designed to enhance the antibody-dependent cellular cytotoxicity effect of monoclonal antibodies to drive B-cell depletion. Artiva Biotherapeutics Inc operates in the biotechnology industry…
Artiva Biotherapeutics Inc is a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies for patients with autoimmune diseases and cancers. The company's lead product candidate AlloNK is an allogeneic off-the-shelf cryopreserved NK cell therapy designed to enhance the antibody-dependent cellular cytotoxicity effect of monoclonal antibodies to drive B-cell depletion. Artiva Biotherapeutics Inc operates in the biotechnology industry with a focus on cell therapy development and manufacturing.
The company generates revenue through the development and potential commercialization of its product candidates, primarily AlloNK and its CAR-NK programs such as AB-201 and AB-205. Revenue is expected to come from future sales of approved therapies, collaboration payments, and licensing agreements. Artiva Biotherapeutics Inc currently has no commercial products on the market and is in the clinical development stage.
The company operates through the following segments:
- AlloNK segment focuses on the development of an allogeneic off-the-shelf NK cell therapy for autoimmune diseases and cancers, currently being evaluated in combination with B-cell targeted monoclonal antibodies in clinical trials for lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, vasculitis, and non-Hodgkin lymphoma.
- CAR-NK programs segment includes AB-201 a HER2-targeted CAR-NK cell product candidate and AB-205 a CD5-directed CAR-NK cell product candidate, both utilizing cord blood starting material and expressing IL-15 for enhanced viability and potency.
Artiva Biotherapeutics Inc holds a first-mover advantage in the autoimmune cell therapy space as the first allogeneic off-the-shelf NK cell therapy to receive Investigational New Drug clearance and Fast Track designation for autoimmune disease indications in the United States. The company competes with other cell therapy companies such as Fate Therapeutics Nkarta Inc and Kyverna Therapeutics Inc but differentiates itself through its scalable manufacturing process lower cost of goods and outpatient administration potential. Its competitive strengths include a proprietary manufacturing platform versatility in monoclonal antibody combinations and a strong scientific advisory board.
The company serves patients with autoimmune diseases such as lupus nephritis rheumatoid arthritis pemphigus vulgaris vasculitis and systemic lupus erythematosus as well as patients with cancers including non-Hodgkin lymphoma Hodgkin lymphoma and solid tumors expressing HER2 or CD5. Artiva Biotherapeutics Inc also collaborates with clinical sites such as Integral Rheumatology & Immunology Specialists in Florida for investigator-initiated trials and partners with companies like Affimed N. V. for collaborator-funded trials.